Skip to main content
Journal cover image

MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)

Publication ,  Conference
Dholaria, B; Bahlis, N; Raje, N; Costello, C; Solh, M; Levy, M; Tomasson, M; Dube, H; Damore, M; Lon, HK; Basu, C; Skoura, A; Chan, E ...
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2021

Duke Scholars

Published In

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

EISSN

2152-2669

ISSN

2152-2650

Publication Date

2021

Volume

21

Start / End Page

S17 / S17

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dholaria, B., Bahlis, N., Raje, N., Costello, C., Solh, M., Levy, M., … Lesokhin, A. (2021). MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 21, pp. S17–S17).
Dholaria, Bhagirathbhai, Nizar Bahlis, Noopur Raje, Caitlin Costello, Melhem Solh, Moshe Levy, Michael Tomasson, et al. “MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM).” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21:S17–S17, 2021.
Dholaria B, Bahlis N, Raje N, Costello C, Solh M, Levy M, Tomasson M, Dube H, Damore M, Lon HK, Basu C, Skoura A, Chan E, Trudel S, Jakubowiak A, Chu M, Gasparetto C, Dalovisio A, Sebag M, Lesokhin A. MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S17–S17.
Journal cover image

Published In

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

EISSN

2152-2669

ISSN

2152-2650

Publication Date

2021

Volume

21

Start / End Page

S17 / S17

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences